Action	Compliance time	Procedures
	(A) For existing attach joints: Within 500 hours TIS or 12 calendar months, whichever occurs first, after the initial inspection; and thereafter at intervals not to exceed 500 hours TIS or 12 calendar months, whichever occurs first. The first repetitive inspection starts at 12 calendar months after the last inspection for those airplanes that already had the initial inspection accomplished since December 27, 1999 (9 months before the effective date of this AD). (B) For new attach joints: Upon accumulating 3,000 hours TIS on the joint, and thereafter at intervals not to exceed 500 hours TIS or 12 calendar months, whichever occurs first.	
(2) After each inspection, repair corrosion damage found to the extent allowed in the service bulletin and apply anti-corrosion protection.	Prior to further flight after the inspection where the discrepancy was found.	In accordance with the procedures in Polskie Zak Ady Lotnicze Co. Ltd. Service Bulletin No. E/02.170/2000, dated August 3, 2000.
(3) After each inspection, replace the wing attach joints if found cracked or if the corrosion damage is more than is specified in the service bulletin.	Prior to further flight after the inspection where the discrepancy was found.	In accordance with the procedures in Polskie Zak Ady Lotnicze Co. Ltd. Service Bulletin No. E/02.170/2000, dated August 3, 2000.
(4) After each inspection, eliminate any ovalization of the wing main joint holes.	Prior to further flight after the inspection where the discrepancy was found.	In accordance with the procedures in Polskie Zak Ady Lotnicze Co. Ltd. Service Bulletin No. E/02.170/2000, dated August 3, 2000.

(e) *Can I comply with this AD in any other way?* You may use an alternative method of compliance or adjust the compliance time if:

(1) Your alternative method of compliance provides an equivalent level of safety; and

(2) The Manager, Small Airplane Directorate, approves your alternative. Submit your request through an FAA Principal Maintenance Inspector, who may add comments and then send it to the Manager, Small Airplane Directorate.

Note: This AD applies to each airplane identified in paragraph (a) of this AD, regardless of whether it has been modified, altered, or repaired in the area subject to the requirements of this AD. For airplanes that have been modified, altered, or repaired so that the performance of the requirements of this AD is affected, the owner/operator must request approval for an alternative method of compliance in accordance with paragraph (e) of this AD. The request should include an assessment of the effect of the modification, alteration, or repair on the unsafe condition addressed by this AD; and, if you have not eliminated the unsafe condition, specific actions you propose to address it.

(f) *Where can I get information about any already-approved alternative methods of compliance?* Contact the Small Airplane Directorate, 901 Locust, Room 301, Kansas City, Missouri 64106; telephone: (816) 329–4121; facsimile: (816) 329–4091.

(g) *What if I need to fly the airplane to another location to comply with this AD?* The FAA can issue a special flight permit under sections 21.197 and 21.199 of the Federal Aviation Regulations (14 CFR 21.197 and 21.199) to operate your airplane to a location where you can accomplish the requirements of this AD.

(h) *Are any service bulletins incorporated into this AD by reference?* You must accomplish the actions required by this AD in accordance with Polskie Zak Ady Lotnicze Co. Ltd. Service Bulletin No. E/02.170/2000, dated August 3, 2000. The Director of the Federal Register approved this incorporation by reference under 5 U.S.C. 552(a) and 1 CFR part 51. You can get copies from Polskie Zaklady Lotnicze Spolka zo.o., Wojska Polskiego 3, 39–300 Mielec, Poland. You may look at copies at FAA, Central Region, Office of the Regional Counsel, 901 Locust, Room 506, Kansas City, Missouri, or at the Office of the Federal Register, 800 North Capitol Street, NW, suite 700, Washington, DC.

(i) *When does this amendment become effective?* This amendment becomes effective on September 27, 2000.

Issued in Kansas City, Missouri, on September 5, 2000.

Michael Gallagher,

Manager, Small Airplane Directorate, Aircraft Certification Service.

[FR Doc. 00–23322 Filed 9–14–00; 8:45 am]

BILLING CODE 4910–13–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

21 CFR Part 558

New Animal Drugs for Use in Animal Feeds; Narasin and Bacitracin Zinc

AGENCY: Food and Drug Administration, HHS.

ACTION: Final rule.

SUMMARY: The Food and Drug Administration (FDA) is amending the animal drug regulations to reflect approval of a new animal drug application (NADA) filed by Roche Vitamins, Inc. The NADA provides for use of approved narasin and bacitracin zinc Type A medicated articles to make two-way combination Type C medicated feeds used for prevention of coccidiosis, increased rate of weight gain, and improved feed efficiency in broiler chickens.

DATES: This rule is effective September 15, 2000.

FOR FURTHER INFORMATION CONTACT: Charles J. Andres, Center for Veterinary Medicine (HFV128), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 301–827–1600.

SUPPLEMENTARY INFORMATION: Roche Vitamins, Inc., 45 Waterview Blvd., Parsippany, NJ 07054–1298, filed NADA 140–865 that provides for use of Monteban® (36, 45, 54, 72, or 90 grams per pound (g/lb) narasin activity) and Baciferm® (10, 25, 40, or 50 g/lb bacitracin activity as bacitracin zinc) Type A medicated articles to make two-way combination Type C medicated feeds for broiler chickens. The combination Type C medicated feeds contain 54 to 72 g/ton narasin and 4 to 50 g/ton bacitracin zinc and are used for prevention of coccidiosis caused by *Eimeria necatrix*, *E. tenella*, *E. acervulina*, *E. brunetti*, *E. mivati*, and *E. maxima*; and for increased rate of weight gain and improved feed efficiency in broiler chickens. The NADA is approved as of August 7, 2000, and the regulations are amended in §§ 558.78 and 558.363 (21 CFR 558.78 and 558.363) to reflect the approval. The basis of approval is discussed in the freedom of information summary.

Section 558.78 is also amended editorially to consolidate the cross-references for approved combinations in paragraph (d)(3) and list them in alphabetical order.

In accordance with the freedom of information provisions of 21 CFR part 20 and 514.11(e)(2)(ii), a summary of safety and effectiveness data and information submitted to support approval of this application may be seen in the Dockets Management Branch (HFA–305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852, between 9 a.m. and 4 p.m., Monday through Friday.

The agency has determined under 21 CFR 25.33(a)(2) that this action is of a type that does not individually or cumulatively have a significant effect on the human environment. Therefore, neither an environmental assessment nor an environmental impact statement is required.

This rule does not meet the definition of ''rule'' in 5 U.S.C. 804(3)(A) because it is a rule of ''particular applicability.'' Therefore, it is not subject to the congressional review requirements in 5 U.S.C. 801–808.

List of Subjects in 21 CFR Part 558

Animal drugs, Animal feeds.

Therefore, under the Federal Food, Drug, and Cosmetic Act and under authority delegated to the Commissioner of Food and Drugs and redelegated to the Center for Veterinary Medicine, 21 CFR part 558 is amended as follows:

PART 558—NEW ANIMAL DRUGS FOR USE IN ANIMAL FEEDS

1. The authority citation for 21 CFR part 558 continues to read as follows:

Authority: 21 U.S.C. 360b, 371.

2. Section 558.78 is amended by revising paragraph (d)(3) to read as follows:

§ 558.78 Bacitracin zinc.

* * * * *

(d) * * *

(3) It may be used as approved in combination with:

(i) Amprolium alone and with roxarsone as in § 558.55.

(ii) Amprolium and ethopabate alone and with roxarsone as in § 558.58.

(iii) Carbarsone as in § 558.120.

(iv) Clopidol alone and with roxarsone as in § 558.175.

(v) Decoquinate alone and with roxarsone as in § 558.195.

(vi) Hygromycin B alone and with penicillin as in § 558.274.

(vii) Lasalocid sodium alone or with roxarsone as in § 558.311.

(viii) Monensin alone and with roxarsone as in § 558.355.

(ix) Naracin as in § 558.363.

(x) Robenidine as in § 558.515.

(xi) Salinomycin alone and with roxarsone as in § 558.550.

(xii) Zoalene alone and with arsanilic acid or roxarsone as in § 558.680.

3. Section 558.363 is amended by adding paragraphs (a)(7) and (d)(1)(x) to read as follows:

§ 558.363 Narasin.

(a) * * *

(7) To 063238: 36, 45, 54, 72, or 90 grams per pound, with 10, 25, 40, or 50 grams per pound bacitracin zinc, paragraph (d)(1)(x) of this section.

* * * * *

(d) * * *

(1) * * *

(x) *Amount per ton*. Narasin, 54 to 72 grams and bacitracin zinc, 4 to 50 grams.

(A) *Indications for use*. For the prevention of coccidiosis caused by *Eimeria necatrix*, *E. tenella*, *E. acervulina*, *E. brunetti*, *E. mivati*, and *E. maxima*, and for increased rate of weight gain and improved feed efficiency.

(B) *Limitations*. For broiler chickens only. Feed continuously as sole ration. Do not allow adult turkeys, horses, or other equines access to formulations containing narasin. Ingestion of narasin by these species has been fatal. Narasin as provided by 000986, bacitracin zinc by 063238 in § 510.600(c) of this chapter.

* * * * *

Dated: August 5, 2000.

Stephen F. Sundlof,

Director, Center for Veterinary Medicine.

[FR Doc. 00–23799 Filed 9–14–00; 8:45 am]

BILLING CODE 4160–01–F

PENSION BENEFIT GUARANTY CORPORATION

29 CFR Parts 4022 and 4044

Benefits Payable in Terminated Single-Employer Plans; Allocation of Assets in Single-Employer Plans; Interest Assumptions for Valuing and Paying Benefits

AGENCY: Pension Benefit Guaranty Corporation.

ACTION: Final rule.

SUMMARY: The Pension Benefit Guaranty Corporation's regulations on Benefits Payable in Terminated Single-Employer Plans and Allocation of Assets in Single-Employer Plans prescribe interest assumptions for valuing and paying benefits under terminating single-employer plans. This final rule amends the regulations to adopt interest assumptions for plans with valuation dates in October 2000. Interest assumptions are also published on the PBGC's web site (http://www.pbgc.gov).

EFFECTIVE DATE: October 1, 2000.

FOR FURTHER INFORMATION CONTACT: Harold J. Ashner, Assistant General Counsel, Office of the General Counsel, Pension Benefit Guaranty Corporation, 1200 K Street, NW., Washington, DC 20005, 202–326-4024. (For TTY/TDD users, call the Federal relay service toll-free at 1–800–877–8339 and ask to be connected to 202–326–4024.)

SUPPLEMENTARY INFORMATION: The PBGC's regulations prescribe actuarial assumptions—including interest assumptions—for valuing and paying plan benefits of terminating single-employer plans covered by title IV of the Employee Retirement Income Security Act of 1974. The interest assumptions are intended to reflect current conditions in the financial and annuity markets.

Three sets of interest assumptions are prescribed: (1) a set for the valuation of benefits for allocation purposes under section 4044 (found in Appendix B to Part 4044), (2) a set for the PBGC to use to determine whether a benefit is payable as a lump sum and to determine lump-sum amounts to be paid by the PBGC (found in Appendix B to Part 4022), and (3) a set for private-sector pension practitioners to refer to if they wish to use lump-sum interest rates determined using the PBGC's historical methodology (found in Appendix C to Part 4022). (See the PBGC's two final rules published March 17, 2000, in the **Federal Register** (at 65 FR 14752 and 14753). Effective May 1, 2000, these rules changed how the interest assumptions are used and where they are set forth in the PBGC's regulations.)

Accordingly, this amendment (1) adds to Appendix B to Part 4044 the interest assumptions for valuing benefits for allocation purposes in plans with valuation dates during October 2000, (2) adds to Appendix B to Part 4022 the interest assumptions for the PBGC to use for its own lump-sum payments in plans with valuation dates during October 2000, and (3) adds to Appendix C to Part 4022 the interest assumptions for private-sector pension practitioners to refer to if they wish to use lump-sum interest rates determined using the PBGC's historical methodology for valuation dates during October 2000.

For valuation of benefits for allocation purposes, the interest assumptions that